Do we need another atypical antipsychotic?

European Neuropsychopharmacology

Volumn 18, Issue SUPPL. 3, 2008, Pages

  Kasper, Siegfried ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antipsychotic therapy; Safety; Schizophrenia; Treatment efficacy

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; DROPERIDOL; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALPERIDONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; UNCLASSIFIED DRUG; ZIPRASIDONE;

AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EJACULATION DISORDER; EXTRAPYRAMIDAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PATIENT SELECTION; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QUALITY OF LIFE; RHINITIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYMPTOM; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; COGNITION; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMIDAZOLES; INDOLES; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SUICIDE;

EID: 50149103194     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.04.006     Document Type: Article

References (43)

1. Alvir J.M., Lieberman J.A., Safferman A.Z., Scwimmer J.L., and Schaaf J.A. Clozapine-induced agranulocytosis - incidence and risk factors in the United States. N. Engl. J. Med. 329 (1993) 162-167
2. Angst J., Jaenicke U., Padrutt A., and Scharfetter C. Ergebnisse eines Doppelblindversuches von HF 1854 (8-Chlor-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e)1,4)diazepin) im Vergleich zu Levomepromazin. Pharmakopsychiatrie 4 (1971) 192-200
3. Arnt J., and Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18 (1998) 63-101
4. Azorin J.M., Strub N., and Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. Int. Clin. Psychopharmcol. 21 (2006) 49-56
5. Carpenter Jr. W.T., Heinrichs D.W., and Alphs L.D. Treatment of negative symptoms. Schizophr. Bull. 11 3 (1985) 440-452
6. Casey D.E. Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology (Berl) 53 suppl 99 (1989) S47-S53
7. Clozaril® (clozapine). Prescribing Information (2005), © Novartis Pharmaceuticals Corporation
8. Clozaril® (clozapine). Summary of Product Characteristics (2005), © Novartis Pharmaceuticals UK Ltd
9. Daniel D.G., Wozniak P., Mack R.J., McCarthy B.G., and Sertindole Study Group. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacol. Bull. 34 (1998) 61-69
10. Domeney A.M., Arnt J., Costall B., Naylor R.J., Sanchez C., and Smith A.G. Effect of sertindole on raised mesolimbic dopaminergic activity in the rat. Drug. Dev. Res. 31 (1994) 175-185
11. Eckardt L., Breithardt G., and Haverkamp W. Electrophysiological characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsdaogenic potential despite QT prolongation. J. Phamacol. Exp. Ther. 300 (2002) 64-71
12. Gallhofer B., Jaanson P., Mittoux A., Tanghøj P., Lis S., and Krieger S. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 40 (2007) 275-286
13. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. B.M.J. 321 (2000) 1371-1376
14. Hale A.S. A review of the safety and tolerability of sertindole. Int. Clin. Psychopharmacol. 13 suppl 3 (1998) S65-S70
15. Hale A., Azorin J.-M., Kasper S., Maier W., Syvälahti E., van der Burght M., Sloth-Nielsen M., and Wehnert A. Sertindole improves both the positive and negative symptoms of schizophrenia: Results of a phase III trial. Int. J. Psych. Clin. Pract. 4 (2000) 55-62
16. Haverkamp W., Eckardt L., Matz J., and Frederiksen K. Sertindole: cardiac electrophysiological profile. Int. J. Psych. Clin. Pract. 6 suppl 1 (2002) S11-S20
17. Kane J.M., Woerner M.G., Pollack S., Safferman A.Z., and Lieberman J.A. Does clozapine cause tardive dyskinesia?. J. Clin. Psychiatry 54 (1993) 327-330
18. Kane J.M. Sertindole: a review of clinical efficacy. Int. Clin. Psychopharmacol. 13 Supplement 3 (1998) S59-S64
19. Kasper S. Negative symptoms and sertindole. Eur. Neuropsychopharmacol. 6 suppl. 4 (1996) S4-S13
20. Kasper S. Sertindole: safety and tolerability profile. Int. J. Psych. Clin. Pract. suppl. 1 (2002) S27-S32
21. 123I-IBZM SPECT study. Psychopharmacology 136 4 (1998) 367-373
22. Kasper S., Quiner S., and Pezawas L. A review of the benefit-risk profile of sertindole. Int. J. Psych. Clin. Pract. 2 Suppl. 2 (1998) S59-S64
23. Kasper S., Hale A.S., Azorin J.M., and Möller H.J. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia. Eur. Arch. Psychiatry. Clin. Neurosci. 249 suppl. 2 (1999) 1-14
24. Kasper S., Quiner S., Pezawas L., Barnas C., Aschauer H., and Küfferle B. The efficacy of sertindole on the positive and negative symptoms of schizophrenia. In: Sacchetti E., and Spano P.F. (Eds). Advances in Preclinical and Clinical Psychiatry (2000), Excerpta Medica, Milano 47-56
25. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res 35 1 (1999) 51-68
26. Leucht S., Barnes T.R.E., Kissling W., Engel R.R., Correll C., and Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory met-analysis of randomised, controlled trials. Am. J. Psychiatry 160 (2003) 1209-1222
27. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K., and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 12 (2005) 1209-1223
28. Lindström E., Farde L., Eberhard J., and Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int. J. Neuropsychopharmacol. 8 (2005) 615-629
29. Lis S., Krieger S., Gallhofer B., Torre P., Mittoux A., and Menard F. Sertindole is Superior to Haloperidol in Cognitive Performance in Patients with Schizophrenia: A Comparative Study. Poster presented at ECNP. Prague, 20-24 September (2003)
30. © 1995 (2003), Blackwell Science Ltd
31. Medicines and Healthcare Regulatory Agency (2001). http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&useSeconda ry=true&ssDocName=CON019548&ssTargetNodeId=221 Accessed on 4 January 2007
32. Meltzer H.Y. Suicide in schizophrenia: Risk factors and clozapine treatment. J. Clin. Psychiatry 59 suppl 3 (1998) 15-20
33. Moore N. Higher cardiovascular mortality with sertindole in ADROIT: A signal not confirmed. Int. J. Psych. Clin. Pract. 6 suppl 1 (2002) S3-S9
34. Perquin L., and Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS. Drugs 18 suppl 2 (2004) 41-43
35. Rosack J. Ziprasidone finally completes FDA's obstacle course. Psychiatr. News 36 (2001) 33
36. Rosenheck R., Perlick D., Bingham S., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomised controlled trial. JAMA 290 (2003) 2693-2702
37. Sanchez C., Arnt J., Dragsted N., Hyttel J., Lembøl H.L., Meier E., Perregaard J., and Skarsfeldt T. Neurochemical and in vivo pharmacological profile of Sertindole, a limbic-selective neuroleptic compound. Drug Dev. Res. 22 (1991) 239-250
38. Schuck P., van der Ameele H., Jaason P., Ryckmans V., and Hawley C. Case histories illustrating the utility of sertindole in clinical practice. CNS. Drugs 18 suppl 2 (2004) 31-40
39. Serdolect® (sertindole). Summary of Product Characteristics (2005), H. Lundbeck A/S September
40. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurones in rats: acute and repeated treatment. Synapse 10 (1992) 25-33
41. Tenback D.E., van Harten P.N., Slooff C.J., Belger M.A., van Os J., and SOHO Study Group. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J. Clin. Psychiatry 66 9 (2005) 1130-1133
42. van Kammen D.P., McEvoy J.P., Targum S.D., Kardatzke D., Sebree T.B., and Sertindole Study Group. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 124 (1996) 168-175
43. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G., Mack R.J., Wozniak P.J., Sebree T.B., Wallin B.A., Kashkin K.B., and Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am. J. Psychiatry 154 (1997) 782-791